Clinical Trial Update: ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ADC with hypofractionated radiotherapy followed by sequential PD-1/PD-L1 blockade with GM-CSF and IL-2 for HER-2 positive adva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoma
• Her-2 Positive Advanced Solid Tumors
• Solid Tumor

Drugs mentioned

• ADC
• GM-CSF (granulocyte-macrophage colony-stimulating factor)
• IL-2 (Interleukin-2)
• PD-1/PD-L1 (PD-1/PD-L1 inhibitors)

Snippet

Sponsor: Second Affiliated Hospital of Soochow University | Conditions: Carcinoma, Solid Tumor | Phase 2 | Status: UNKNOWN